Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology

Rev Esp Cardiol (Engl Ed). 2020 Sep;73(9):749-757. doi: 10.1016/j.rec.2020.04.025. Epub 2020 Jun 19.
[Article in English, Spanish]

Abstract
in English, Spanish

The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy.

La pandemia producida por la infección del nuevo coronavirus SARS-CoV-2, que da lugar a una enfermedad altamente contagiosa (COVID-19), ha producido un colapso de los sistemas sanitarios de todo el mundo. Se ha descrito que estos pacientes sufren un estado inflamatorio que condiciona un alto riesgo trombótico. Sin embargo, apenas hay información sobre cómo abordar el riesgo trombótico, la coagulopatía y el tratamiento anticoagulante de estos pacientes. Por otra parte, incluso los pacientes no infectados por COVID-19 sufren una tremenda influencia en su abordaje habitual por la situación sanitaria actual. El objetivo del presente documento, elaborado por el Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Española de Cardiología, es presentar la información disponible y dar unas pautas sencillas de tratamiento con fármacos antitrombóticos.

Keywords: Antithrombotics; Antitrombóticos; COVID-19; Coronavirus; SARS-CoV-2; Thrombosis; Trombosis.

MeSH terms

  • Betacoronavirus*
  • COVID-19
  • COVID-19 Drug Treatment
  • Cardiology
  • Coronavirus Infections / drug therapy*
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Pandemics
  • Patient Selection
  • Pneumonia, Viral / drug therapy*
  • SARS-CoV-2
  • Societies, Medical
  • Spain

Substances

  • Fibrinolytic Agents